10x Genomics (NASDAQ:TXG – Get Free Report) was upgraded by equities researchers at Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday, Wall Street Zen reports.
Several other research analysts have also recently commented on the company. Leerink Partners increased their price target on 10x Genomics from $40.00 to $90.00 and gave the company a “market perform” rating in a research report on Tuesday, September 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 10x Genomics in a research report on Monday, September 21st. JPMorgan Chase & Co. dropped their price objective on 10x Genomics from $70.00 to $65.00 and set a “neutral” rating on the stock in a research note on Monday, November 9th. TD Cowen upped their price objective on 10x Genomics from $47.00 to $70.00 and gave the stock a “hold” rating in a research note on Tuesday, October 13th. Finally, Stephens downgraded 10x Genomics from an “overweight” rating to an “equal weight” rating in a report on Friday, October 23rd. Five analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $68.40.
View Our Latest Stock Analysis on 10x Genomics
10x Genomics Stock Performance
NASDAQ TXG opened at $58.19 on Friday. The stock’s 50 day moving average price is $73.92 and its two-hundred day moving average price is $42.57. The stock has a market capitalization of $7.65 billion, a price-to-earnings ratio of -111.90 and a beta of 2.03. 10x Genomics has a 52 week low of $15.12 and a 52 week high of $102.81.
10x Genomics (NASDAQ:TXG – Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.12. The firm had revenue of $150.67 million for the quarter, compared to analyst estimates of $147.96 million. 10x Genomics had a negative net margin of 10.84% and a negative return on equity of 8.19%. The company’s revenue was up 1.1% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.22) EPS. On average, equities research analysts forecast that 10x Genomics will post -0.74 EPS for the current year.
Insider Buying and Selling at 10x Genomics
In other 10x Genomics news, CFO Adam Taich sold 46,388 shares of the business’s stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $64.57, for a total transaction of $2,995,273.16. Following the transaction, the chief financial officer owned 316,344 shares of the company’s stock, valued at $20,426,332.08. The trade was a 12.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Serge Saxonov sold 31,000 shares of the business’s stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $62.90, for a total value of $1,949,900.00. Following the transaction, the chief executive officer directly owned 1,019,249 shares in the company, valued at approximately $64,110,762.10. This trade represents a 2.95% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 190,333 shares of company stock valued at $12,604,970 in the last three months. Corporate insiders own 8.84% of the company’s stock.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the business. Entropy Technologies LP acquired a new position in 10x Genomics in the 3rd quarter valued at about $1,293,000. FORA Capital LLC acquired a new stake in 10x Genomics during the third quarter worth approximately $496,000. Pathstone Holdings LLC acquired a new stake in 10x Genomics during the third quarter worth approximately $560,000. Marshall Wace LLP acquired a new position in shares of 10x Genomics in the third quarter valued at approximately $4,954,000. Finally, Empowered Funds LLC increased its stake in shares of 10x Genomics by 384.6% during the third quarter. Empowered Funds LLC now owns 38,252 shares of the company’s stock worth $3,456,000 after purchasing an additional 30,358 shares during the period. 84.68% of the stock is owned by institutional investors and hedge funds.
10x Genomics Company Profile
10x Genomics, Inc. develops technology for studying biological systems at single-cell and spatial resolution. Its instruments, consumables and software help researchers analyze gene expression and other features of cells while preserving information about their location within tissue. The company’s product platforms include Chromium for single-cell analysis, Visium for spatial gene-expression analysis and Xenium for in situ analysis of gene activity within tissue samples. Its tools are used in areas such as immunology, neuroscience, cancer research and drug discovery.
Further Reading
- Five stocks we like better than 10x Genomics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.
